- Home
- CRBP vs VIGL Comparison
CRBP vs VIGL Comparison
Compare CRBP & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- VIGL
- Stock Information
- Founded
- CRBP 2009
- VIGL 2020
- Country
- CRBP United States
- VIGL United States
- Employees
- CRBP N/A
- VIGL N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- CRBP Health Care
- VIGL Health Care
- Exchange
- CRBP Nasdaq
- VIGL Nasdaq
- Market Cap
- CRBP 73.4M
- VIGL 74.7M
- IPO Year
- CRBP N/A
- VIGL 2022
- Fundamental
- Price
- CRBP $6.65
- VIGL $2.41
- Analyst Decision
- CRBP Strong Buy
- VIGL Strong Buy
- Analyst Count
- CRBP 10
- VIGL 5
- Target Price
- CRBP $53.56
- VIGL $16.33
- AVG Volume (30 Days)
- CRBP 148.0K
- VIGL 164.4K
- Earning Date
- CRBP 05-06-2025
- VIGL 05-07-2025
- Dividend Yield
- CRBP N/A
- VIGL N/A
- EPS Growth
- CRBP N/A
- VIGL N/A
- EPS
- CRBP N/A
- VIGL N/A
- Revenue
- CRBP N/A
- VIGL N/A
- Revenue This Year
- CRBP N/A
- VIGL N/A
- Revenue Next Year
- CRBP $150.00
- VIGL N/A
- P/E Ratio
- CRBP N/A
- VIGL N/A
- Revenue Growth
- CRBP N/A
- VIGL N/A
- 52 Week Low
- CRBP $4.64
- VIGL $1.31
- 52 Week High
- CRBP $61.90
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- CRBP 48.86
- VIGL 60.07
- Support Level
- CRBP $6.10
- VIGL $1.75
- Resistance Level
- CRBP $8.07
- VIGL $3.00
- Average True Range (ATR)
- CRBP 0.70
- VIGL 0.26
- MACD
- CRBP -0.07
- VIGL 0.08
- Stochastic Oscillator
- CRBP 26.50
- VIGL 55.30
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.